Acute Kidney Injury (AKI) Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Acute Kidney Injury (AKI) formerly known as Acute Renal Failure (ARF) is caused due to the sudden decrease in the renal or kidney function. This means that the kidney has lost it ability to filter waste and toxins from the body including the dysregulation of extracellular fluid volume. AKI can be classified into intrinsic, pre-renal and post-renal obstructive nephropathy. Out of the three, the intrinsic AKI is considered to be the true kidney disease while the others are the results of other renal diseases leading to intrinsic kidney disease which further lead to a decrease in the glomerular filtration rate (GFR). A severe increase in the serum creatinine levels and urine output is an indication of acute kidney injury apart from GFR fall.
The report provides Acute Kidney Injury (AKI) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Orion Corporation, Baxter, Quark and Sentien Biotechnologies, Inc. and Pharma Group NV among others.